article thumbnail

Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents

FDA Law Blog: Biosimilars

Koblitz — As we have noted for the last year or so, the FTC has been on a mission to clean up the Orange Book by removing what it deems to be “improper” patents. FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug. And on X (R.I.P.

FDA 116
article thumbnail

Synthetic biology e-book out now  

Drug Discovery World

This e-book , sponsored by Evonetix, contains exclusive insight from industry experts on how synthetic biology is innovating and advancing drug discovery. . The post Synthetic biology e-book out now appeared first on Drug Discovery World (DDW). Key topics include: . Four key approaches to synthetic biology . Access it here.

Drugs 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Legislative Proposals to Tackle Improper Pharmaceutical Patents in the Orange Book

Drug Patent Watch

A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers.

article thumbnail

Announcing Our First Book: Origins

Codon

Our first book, Origins , is now available for purchase. The book is an ode to scientific progress, and the articles within tell stories about everything from the origins of synthetic biology to the discovery of an antimalarial drug in China and the invention of the micropipette. Purchase the Book You can read that here.

article thumbnail

Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends

Drug Patent Watch

Brinckerhoff discusses trends in Inter Partes Review (IPR) and Post Grant Review (PGR) proceedings involving Orange Book and biologic patents, based… The post Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends appeared first on DrugPatentWatch - Make Better Decisions.

98
article thumbnail

FTC Continues to Rage Against Device Patent Listings in the Orange Book

FDA Law Blog: Biosimilars

Koblitz — The FTC appears to be on a mission to cleanse the Orange Book of patents it deems improperly listed. For the second time in recent years, the FTC has filed an Amicus Brief explaining exactly which patents should not be in the Orange Book.

FDA 59
article thumbnail

Evolution's recipe book: How 'copy paste' errors cooked up the animal kingdom

Science Daily: Pharmacology News

A series of whole genome and gene duplication events that go back hundreds of millions of years have laid the foundations for tissue-specific gene expression, according to a new study.

120
120